Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.69 |
| ▸ | DRD3 | P35462 | 14/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.66 |
| ▸ | HTR2A | P28223 | 5/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051887 | 0.87 | DRD2 (0.63) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7052921 | 0.87 | DRD2 (0.70) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7057222 | 0.83 | DRD2 (0.77) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7056412 | 0.83 | DRD2 (0.73) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7056355 | 0.83 | DRD2 (0.73) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7056313 | 0.81 | DRD3 (0.73) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7058045 | 0.81 | DRD2 (0.75) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7053778 | 0.76 | DRD2 (0.76) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL7056826 | 0.75 | DRD3 (0.64) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL8147822 | 0.75 | DRD2 (0.77) | DRD2DRD3ADRA1AHTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003028728-A1 | 4-(4-SUBSTITUTED PIPERAZINYL-1YL)-BUTYLCARBOXAMIDES AS D3 DOPAMINE SUBTYPE SELECTIVE LIGANDS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-04-10 | — | — | WO | disclosed |